Qianhai Health Holdings Limited (0911.HK)
HKD 0.27
(0.0%)
HKD 0.27
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 94 Million HKD | -3.81% |
| 2022 | 97.72 Million HKD | 43.52% |
| 2021 | 68.09 Million HKD | 9.32% |
| 2020 | 62.28 Million HKD | -49.64% |
| 2019 | 123.67 Million HKD | 117.07% |
| 2018 | 56.97 Million HKD | -53.69% |
| 2017 | 123.03 Million HKD | 536.77% |
| 2016 | 19.32 Million HKD | -98.94% |
| 2015 | 1.82 Billion HKD | -11.63% |
| 2014 | 2.06 Billion HKD | 167.71% |
| 2013 | 770.65 Million HKD | 29.03% |
| 2012 | 597.28 Million HKD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 125.45 Million HKD | 33.46% |
| 2024 Q2 | 125.45 Million HKD | 0.0% |
| 2023 Q3 | 94 Million HKD | 1.22% |
| 2023 Q1 | 92.86 Million HKD | -4.97% |
| 2023 FY | 94 Million HKD | -3.81% |
| 2023 Q2 | 92.86 Million HKD | 0.0% |
| 2023 Q4 | 94 Million HKD | 0.0% |
| 2022 FY | 97.72 Million HKD | 43.52% |
| 2022 Q4 | 97.72 Million HKD | 0.0% |
| 2022 Q3 | 97.72 Million HKD | 246.82% |
| 2022 Q2 | 28.17 Million HKD | 0.0% |
| 2022 Q1 | 28.17 Million HKD | -58.62% |
| 2021 FY | 68.09 Million HKD | 9.32% |
| 2021 Q4 | 68.09 Million HKD | 0.0% |
| 2021 Q2 | 85.77 Million HKD | 0.0% |
| 2021 Q3 | 68.09 Million HKD | -20.61% |
| 2021 Q1 | 85.77 Million HKD | 37.71% |
| 2020 Q3 | 62.28 Million HKD | 24.76% |
| 2020 FY | 62.28 Million HKD | -49.64% |
| 2020 Q2 | 49.92 Million HKD | 0.0% |
| 2020 Q1 | 49.92 Million HKD | -59.63% |
| 2020 Q4 | 62.28 Million HKD | 0.0% |
| 2019 FY | 123.67 Million HKD | 117.07% |
| 2019 Q4 | 123.67 Million HKD | 0.0% |
| 2019 Q3 | 123.67 Million HKD | 145.08% |
| 2019 Q1 | 50.46 Million HKD | -11.43% |
| 2019 Q2 | 50.46 Million HKD | 0.0% |
| 2018 Q1 | 51.36 Million HKD | -58.25% |
| 2018 FY | 56.97 Million HKD | -53.69% |
| 2018 Q4 | 56.97 Million HKD | 0.0% |
| 2018 Q3 | 56.97 Million HKD | 10.92% |
| 2018 Q2 | 51.36 Million HKD | 0.0% |
| 2017 Q1 | 16.29 Million HKD | -15.68% |
| 2017 Q2 | 16.29 Million HKD | 0.0% |
| 2017 FY | 123.03 Million HKD | 536.77% |
| 2017 Q3 | 123.03 Million HKD | 655.21% |
| 2017 Q4 | 123.03 Million HKD | 0.0% |
| 2016 FY | 19.32 Million HKD | -98.94% |
| 2016 Q4 | 19.32 Million HKD | 0.0% |
| 2016 Q3 | 19.32 Million HKD | -96.93% |
| 2016 Q2 | 629.85 Million HKD | 1.31% |
| 2016 Q1 | 621.71 Million HKD | -65.9% |
| 2015 Q3 | 1.82 Billion HKD | -16.28% |
| 2015 Q2 | 2.17 Billion HKD | 0.4% |
| 2015 Q1 | 2.16 Billion HKD | 5.14% |
| 2015 FY | 1.82 Billion HKD | -11.63% |
| 2015 Q4 | 1.82 Billion HKD | 0.0% |
| 2014 Q2 | 498.21 Million HKD | 0.0% |
| 2014 Q1 | 498.21 Million HKD | -35.35% |
| 2014 Q3 | 2.06 Billion HKD | 314.11% |
| 2014 Q4 | 2.06 Billion HKD | 0.0% |
| 2014 FY | 2.06 Billion HKD | 167.71% |
| 2013 Q4 | 770.65 Million HKD | 0.0% |
| 2013 FY | 770.65 Million HKD | 29.03% |
| 2013 Q1 | - HKD | 0.0% |
| 2013 Q3 | 770.65 Million HKD | 0.0% |
| 2012 FY | 597.28 Million HKD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 142.28 Million HKD | 33.932% |
| Grand Pharmaceutical Group Limited | 7.24 Billion HKD | 98.702% |
| Extrawell Pharmaceutical Holdings Limited | 170.4 Million HKD | 44.836% |
| Wai Yuen Tong Medicine Holdings Limited | 709.65 Million HKD | 86.754% |
| Lee's Pharmaceutical Holdings Limited | 930.06 Million HKD | 89.893% |
| Essex Bio-Technology Limited | 903.78 Million HKD | 89.599% |
| Tongfang Kontafarma Holdings Limited | 665.38 Million HKD | 85.872% |
| PuraPharm Corporation Limited | 689.65 Million HKD | 86.369% |
| SSY Group Limited | 4.49 Billion HKD | 97.908% |
| JBM (Healthcare) Limited | 366.75 Million HKD | 74.369% |
| Jacobson Pharma Corporation Limited | 1.09 Billion HKD | 91.38% |
| China Resources Pharmaceutical Group Limited | 168.46 Billion HKD | 99.944% |